Our Pipeline

See where we’re heading

At CureVac, we aim to leverage our unique technology to provide life-saving solutions for patients with the greatest need. That’s why we are moving forward with a strategic, purposeful mRNA-based pipeline focusing on four therapeutic areas in which we can truly make a difference: cancer immunotherapies, antibody therapies, molecular therapies to treat rare diseases, and prophylactic vaccines.

mRNA-based Cancer Immunotherapies

Collaborations
Pre-Clinical Discovery
Pre-Clinical Development
Phase 1
Phase 2
Oncology

CV0903 (Solid tumor program: mRNA intratumoral cocktail)

Collaborations:
Close
Close

Shared neoantigens (5 programs, targets undisclosed)

Collaborations:
Close
Close

mRNA-based Molecular Therapies for Rare Diseases

Collaborations
Pre-Clinical Discovery
Pre-Clinical Development
Phase 1
Phase 2
Rare Diseases

Rare Diseases (Liver)

Collaborations:
Close
Close

Antibody-encoding mRNA

Collaborations:
Close
Close

Undisclosed programs (Eye, Lung)

Collaborations:
Close
Close

mRNA-based Prophylactic Vaccines

Collaborations
Pre-Clinical Discovery
Pre-Clinical Development
Phase 1
Phase 2
Infectious Disease / Prophylactic Vaccines

CEPI

Collaborations:
Close
Close